"Chimerism" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The occurrence in an individual of two or more cell populations of different chromosomal constitutions, derived from different individuals. This contrasts with MOSAICISM in which the different cell populations are derived from a single individual.
| Descriptor ID |
D046528
|
| MeSH Number(s) |
G05.365.590.175.125
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Chimerism".
Below are MeSH descriptors whose meaning is more specific than "Chimerism".
This graph shows the total number of publications written about "Chimerism" by people in this website by year, and whether "Chimerism" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 2 | 1 | 3 |
| 2014 | 1 | 1 | 2 |
| 2015 | 2 | 1 | 3 |
| 2016 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chimerism" by people in Profiles.
-
Donor programmed cell death 1 ligand 1 is required for organ transplant tolerance in major histocompatibility complex-mismatched mixed chimeras although programmed cell death 1 ligand 1 and major histocompatibility complex class II are not required for inducing chimerism. Am J Transplant. 2023 08; 23(8):1116-1129.
-
Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response. Blood Adv. 2020 10 27; 4(20):5146-5156.
-
Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival. Bone Marrow Transplant. 2020 06; 55(6):1161-1168.
-
Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes. Biol Blood Marrow Transplant. 2019 03; 25(3):466-473.
-
Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. Biol Blood Marrow Transplant. 2016 06; 22(6):1065-1072.
-
Lost in translation? Microchimersim detection in experimental and clinical transplantation. Chimerism. 2015 Oct 02; 6(4):51-53.
-
Early Microchimerism After Face Transplantation Detected by Quantitative Real-time Polymerase Chain Reaction of Insertion/Deletion Polymorphisms. Transplantation. 2015 Jul; 99(7):e44-5.
-
Alternative donor transplantation--"mixing and matching": the role of combined cord blood and haplo-identical donor transplantation (haplo-cord SCT) as a treatment strategy for patients lacking standard donors? Curr Hematol Malig Rep. 2015 Mar; 10(1):1-7.
-
Microchimerism in recurrent miscarriage. Cell Mol Immunol. 2014 Nov; 11(6):589-94.
-
Overcoming immunological barriers in regenerative medicine. Nat Biotechnol. 2014 Aug; 32(8):786-94.